News and Events
Upcoming Events
April 21, 2026
April 28 Grants Working Group Meeting
March 16, 2026
March 26 ICOC/ARS Meeting
March 10, 2026
March 19 Science Subcommittee Meeting
March 5, 2026
March 19-20 Grants Working Group Meeting
Latest Press Releases
March 27, 2026
CIRM approves over $111 million to support discovery and clinical research
March 27, 2026
First therapy funded by California taxpayer dollars is approved to treat rare childhood disorder
January 29, 2026
CIRM approves new $100 million plan to accelerate genetic therapies for patients with rare diseases
CIRM’s Blog: The Stem Cellar
The Stem Cellar
- Closer to Cures: Diana Farmer discusses clinical trials for spina bifida April 22, 2026written by Holly Alyssa MacCormick The California Institute for Regenerative Medicine (CIRM) helped fund a clinical trial that involved an experimental stem cell treatment for a frequently paralyzing form of spina bifida. Today, several of those babies are now able to walk and run unassisted. Babies with severe spina bifida are often treated with surgery […]
- First therapy supported by CIRM approved by the FDA March 27, 2026After 21 years (and a few months), the California Institute of Regenerative Medicine (CIRM) has hit a major milestone: the first therapy supported by CIRM has been approved by the Food and Drug Administration for use in patients. In 2004, when California voters created CIRM to fund research with stem cells — cells that can divide to form many different tissues in the body — stem cells […]
- CIRM-funded clinical trial gives siblings a second chance at life March 17, 2026written by Holly Alyssa MacCormick Alicia Langenhop was seven months pregnant with her third child when she and her husband, Jon, learned that their two toddlers had a life-threatening immune disease called leukocyte adhesion deficiency-1 (LAD-1). The odds of being born with LAD-1 are rare, literally one-in-a-million, but the disease is genetic, so the Langenhop’s unborn child had a roughly 25 percent chance of having the disease. […]